Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 19/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18354469 | 0.92 | GBA1 (1.00) | GBA1 | |
| SCHEMBL18354447 | 0.89 | GBA1 (0.76) | GBA1 | |
| SCHEMBL18353966 | 0.88 | GBA1 (1.00) | GBA1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL18354360 | 0.86 | GBA1 (0.73) | GBA1 | |
| SCHEMBL22403157 | 0.84 | GBA1 (0.85) | GBA1 | |
| SCHEMBL20710513 | 0.82 | GBA1 (0.79) | GBA1 | |
| SCHEMBL21790461 | 0.82 | GBA1 (0.81) | GBA1 | |
| SCHEMBL20710508 | 0.81 | GBA1 (0.83) | GBA1 | |
| SCHEMBL22403117 | 0.80 | GBA1 (1.00) | GBA1 | |
| SCHEMBL18354349 | 0.80 | GBA1 (0.58) | GBA1ALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934270-B2 | Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity | NORTHWESTERN UNIVERSITY (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200071292-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY | NORTHWESTERN UNIVERSITY (US) | 2020-03-05 | — | — | US | disclosed |
| US-10167270-B2 | Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity | NORTHWESTERN UNIVERSITY (US) | 2019-01-01 | — | — | US | disclosed |
| US-20170001976-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY | NORTHWESTERN UNIVERSITY (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170001976-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY | NORTHWESTERN UNIVERSITY (US) | 2017-01-05 | — | — | US | disclosed |
| WO-2017004405-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY | NORTHWESTERN UNIVERSITY (US) | 2017-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934270-B2 | Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity | GBA1, GAA, GBA2 | GBA1 1/4885ALDH1A1 2347/4885MAPT 1178/4885 |
| US-20200071292-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY | GBA1, GAA, GBA2 | GBA1 1/4885ALDH1A1 2347/4885MAPT 1178/4885 |
| US-20170001976-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY | GBA1, GAA, GBA2 | GBA1 1/4885ALDH1A1 2347/4885MAPT 1178/4885 |
| US-10167270-B2 | Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity | GBA1, GAA, GBA2 | GBA1 1/4885ALDH1A1 2347/4885MAPT 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.